ALL ALS Consortium enrolls 1,000th participant

The Access for All in ALS (ALL ALS) Consortium has announced enrollment of its 1,000th participant, marking a major milestone for what is designed to be the largest and most inclusive prospective observational biobanking study in ALS.  

The 1,000th participant was enrolled at the University of Utah, under the leadership of Principal Investigator Mark Bromberg, MD. “ALL ALS is an extremely important study to better understand what is behind ALS, and our clinical trials group is very pleased to have been the clinic to reach this milestone in enrollment. We look forward to adding to enrollment and contributing to the ultimate goal of finding effective treatments for ALS,” said Mark Bromberg, MD, PhD, the Chief of the Division of General Neurology at the University of Utah. 

The ALL ALS Consortium launched in 2023 with funding from the National Institutes of Health (NIH), bringing together 36 clinical research sites across the United States and two coordination centers led by researchers at Barrow Neurological Institute and Massachusetts General Hospital. ALL ALS enrolls participants with ALS, those genetically at-risk for developing ALS, and controls.  

“We are incredibly excited to hit the exciting milestone of 1,000 participants enrolled, and we look forward to reaching our enrollment goals by autumn 2026,” said Robert Bowser, PhD, the Chief Scientific Officer and John P. and Betty Van Denburgh Chair of Neuromuscular Disease at Barrow. 

“The ongoing success of ALL ALS is a testament to the incredible community support for the project, indispensable funding from the ACT for ALS, and strong alliance with the NIH and AMP ALS,” said James D. Berry, MD, the Chief of the Mass General Brigham Division of Motor Neuron Diseases and Williamson Winthrop ALS Scholar.

The ALL ALS Consortium continues to expand enrollment and aims to exceed 2,000 participants by the end of September 2026. 

If you are interested in learning more about this study, please email Info@ALL-ALS.org, visit the website at ALL-ALS.org, or follow on Instagram at @all_als_. The ALL ALS Consortium is funded by the National Institutes of Health: OT2NS136939 and OT2NS136938.

About Barrow Neurological Institute
Barrow Neurological Institute, located at Dignity Health St. Joseph's Hospital and Medical Center in Phoenix, is an international leader in treatment, research, and education relating to brain and spinal diseases and injuries. The Institute is one of the busiest centers for neurology and neurosurgery in the United States. Each year, more than 73,000 patients are treated at Barrow with more than 6,000 surgeries performed at the Institute. Because of its high volume, Barrow clinicians are familiar with the rarest and most challenging neurological conditions and are often sought by patients from around the world for life-saving medical care. To learn more about Barrow, please follow us on Facebook, Instagram, LinkedIn and X.

About the Sean M. Healey & AMG Center for ALS at MGB

At the Sean M. Healey & AMG Center for ALS at Mass General Brigham, we are committed to bringing together a global network of scientists, physicians, nurses, foundations, federal agencies, and people living with ALS, their loved ones, and caregivers to accelerate the pace of ALS therapy discovery and development.

Launched in November 2018, the Healey & AMG Center, under the leadership of Merit Cudkowicz, MD and a Science Advisory Council of international experts, is reimagining how to develop and test the most promising therapies to treat the disease, identify cures and ultimately prevent it.

With many clinical trials and lab-based research studies in progress right now, we are ushering in a new phase of ALS treatment and care. Together, we will find the cures.